Accent Therapeutics has revealed promising new preclinical data for its leading clinical programs, ATX-295 and ATX-559, at the prestigious 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The company, renowned for its specialized focus on RNA-modifying enzyme (RME) inhibitors, aims to transform cancer treatment by targeting these innovative molecular pathways. ATX-295 showed significant potential in inhibiting key cancer-related targets, while ATX-559 exhibited robust efficacy in preclinical models, highlighting Accent’s ongoing commitment to pioneering developments in oncology. By unveiling these compelling findings, Accent underscores its strategic goal to address unmet needs in cancer therapy, thereby enhancing clinical outcomes for patients. This presentation is a significant milestone for Accent Therapeutics as it continues to advance its pipeline of novel therapeutics designed to combat cancer more effectively.
PR NewswireNew data shows Britain’s night-time economy shrinks by 350 venues in six months
October 19, 2026
New data reveals a significant decline in Britain’s night-time economy, with 350 venues closing within just six months. This downward trend highlights the ongoing challenges